News

Human Trial with Novel Glaucoma Treatment Rendered a Clinically Meaningful Efficacy Outcome and Positive Safety and Tolerability Data SAN DIEGO--(June 8th, 2023) --Today, MediPrint® Ophthalmics (MediPrint), an emerging San Diego-based clinical stage eye care pharmaceutical company focused on enhancing vision for life, announces it has

Company Also Announces Move into New San Diego Headquarters SAN DIEGO--(November 8th, 2022) --Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on enhancing vision for life, announces it has initiated its SIGHT-2 dose-finding Phase 2b study for its proprietary

Plus, Company Comments on Its Poster at Prestigious American Glaucoma Society Meeting SAN DIEGO--(BUSINESS WIRE) (March 15th, 2022) --Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on enhancing vision for life, announces the initial closing of a Series A

Plus, Company Advances Plans for Phase 2b Trial in 2022 January 19th, 2022 SAN DIEGO--(BUSINESS WIRE)--Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces the acceptance and presentation of a poster highlighting its latest clinical

Plus, Company Receives Patent for Novel Post-Cataract Surgery Lens SAN DIEGO--(BUSINESS WIRE)--Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces enlightening findings from its primary market research with optometrists and ophthalmologists related to contact lens

The Coming Rise of Drug-delivery Contact Lenses This novel new system could mark a significant advancement for eye care. By Melissa Barnett, OD The use of contact lenses as ocular drug delivery systems was first introduced as an idea decades ago. As contact lenses have